Cullinan Therapeutics/$CGEM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cullinan Therapeutics
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Ticker
$CGEM
Sector
Primary listing
Employees
109
Headquarters
Website
CGEM Metrics
BasicAdvanced
$844M
-
-$3.72
-0.16
-
Price and volume
Market cap
$844M
Beta
-0.16
52-week high
$16.74
52-week low
$5.68
Average daily volume
805K
Financial strength
Current ratio
10.248
Quick ratio
10.088
Long term debt to equity
0.466
Total debt to equity
0.656
Profitability
EBITDA (TTM)
-241.337
Management effectiveness
Return on assets (TTM)
-28.22%
Return on equity (TTM)
-44.02%
Valuation
Price to book
2.06
Price to tangible book (TTM)
2.06
Price to free cash flow (TTM)
-4.686
Free cash flow yield (TTM)
-21.34%
Free cash flow per share (TTM)
-2.977
Growth
Earnings per share change (TTM)
19.62%
3-year earnings per share growth (CAGR)
16.09%
What the Analysts think about CGEM
Analyst ratings (Buy, Hold, Sell) for Cullinan Therapeutics stock.
CGEM Financial Performance
Revenues and expenses
CGEM Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cullinan Therapeutics stock?
Cullinan Therapeutics (CGEM) has a market cap of $844M as of March 14, 2026.
What is the P/E ratio for Cullinan Therapeutics stock?
The price to earnings (P/E) ratio for Cullinan Therapeutics (CGEM) stock is 0 as of March 14, 2026.
Does Cullinan Therapeutics stock pay dividends?
No, Cullinan Therapeutics (CGEM) stock does not pay dividends to its shareholders as of March 14, 2026.
When is the next Cullinan Therapeutics dividend payment date?
Cullinan Therapeutics (CGEM) stock does not pay dividends to its shareholders.
What is the beta indicator for Cullinan Therapeutics?
Cullinan Therapeutics (CGEM) has a beta rating of -0.16. This means that it has an inverse relation to market volatility.